Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI

Watchlist Manager
Brainstorm Cell Therapeutics Inc Logo
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Watchlist
Price: 0.5625 USD -6.23% Market Closed
Market Cap: 6.2m USD

Intrinsic Value

The intrinsic value of one BCLI stock under the Base Case scenario is 24.0746 USD. Compared to the current market price of 0.5625 USD, Brainstorm Cell Therapeutics Inc is Undervalued by 98%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BCLI Intrinsic Value
24.0746 USD
Undervaluation 98%
Intrinsic Value
Price
Base Case Scenario
Compare BCLI to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about BCLI?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Brainstorm Cell Therapeutics Inc

Current Assets 2.3m
Cash & Short-Term Investments 1.6m
Receivables 67k
Other Current Assets 621k
Non-Current Assets 1.2m
PP&E 1m
Other Non-Current Assets 204k
Current Liabilities 10.9m
Accounts Payable 6.8m
Accrued Liabilities 981k
Short-Term Debt 1.2m
Other Current Liabilities 1.9m
Non-Current Liabilities 127k
Other Non-Current Liabilities 127k
Efficiency

Free Cash Flow Analysis
Brainstorm Cell Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Brainstorm Cell Therapeutics Inc

Revenue
0 USD
Operating Expenses
-12.3m USD
Operating Income
-12.3m USD
Other Expenses
1.2m USD
Net Income
-11.1m USD
Fundamental Scores

BCLI Profitability Score
Profitability Due Diligence

Brainstorm Cell Therapeutics Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional 3Y Average ROE
Exceptional ROIC
Exceptional ROE
76/100
Profitability
Score

Brainstorm Cell Therapeutics Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

BCLI Solvency Score
Solvency Due Diligence

Brainstorm Cell Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
38/100
Solvency
Score

Brainstorm Cell Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCLI Price Targets Summary
Brainstorm Cell Therapeutics Inc

There are no price targets for BCLI.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Brainstorm Cell Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BCLI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BCLI Insider Trading
Buy and sell transactions by insiders

BCLI News